Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.
7 affiliations
- 1Division of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- 2Oncology Outcomes Research, AstraZeneca, Mississauga, Ontario, Canada.
- 3Oncology Data and Analytics, AstraZeneca, Gaithersburg, Maryland, USA.
- 4Oncology Business Unit, US Medical Affairs, AstraZeneca, Gaithersburg, Maryland, USA.
- 5Oncology Biometrics, AstraZeneca, South San Francisco, California, USA.
- 6Oncology Outcomes Research, AstraZeneca, Cambridge, UK.
- 7Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
Aims
To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.Materials & methods
This retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.Results
Of 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).Conclusion
TARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.
Related
- Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- Treatment Patterns, Treatment Response, and Survival Outcomes in Patients with Multiple Myeloma: A Single-Center Real-World Study
- Post-Recurrence Treatment Patterns and Outcomes After Curative-Intent Multimodality Strategy in Patients with Pleural Mesothelioma: A Retrospective Cohort Study
- Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.
BibTeX
@article{garciareyes2026treatment,
title = {{Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.}},
author = {Kirema Garcia-Reyes and William H Wang and Mufiza Farid-Kapadia and Nehemiah Kebede and Dex L Underwood and Ling Cai and Heide A Stirnadel-Farrant and Cindy Wang and Neehar D Parikh},
journal = {Hepatic oncology},
year = {2026},
month = oct,
doi = {10.1080/20450923.2026.2736861},
url = {https://europepmc.org/article/MED/42895274},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.
AU - Kirema Garcia-Reyes
AU - William H Wang
AU - Mufiza Farid-Kapadia
AU - Nehemiah Kebede
AU - Dex L Underwood
AU - Ling Cai
AU - Heide A Stirnadel-Farrant
AU - Cindy Wang
AU - Neehar D Parikh
PY - 2026
DA - 2026/10/19
JO - Hepatic oncology
DO - 10.1080/20450923.2026.2736861
UR - https://europepmc.org/article/MED/42895274
AB - Aims To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.Materials & methods This retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.Results Of 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).Conclusion TARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.
SN - 2045-0923
SN - 2045-0931
ER -